About
Elaya develops medical device technology to prevent ICU Acquired Weakness (ICUAW) to improve patient outcomes and healthspan. Muscle weakness as a result of sedation and immobility in the ICU costs healthcare payers $11 billion in lengthy ICU stay costs and $22 billion in post-ICU care costs. Patients over 65 on a ventilator for one week have a 50% chance of permanent disability and functional dependence as a result of ICUAW and women have 4 times higher risk of developing ICUAW. Elaya is building a diagnostic sensor to detect and monitor ICUAW and an electrical stimulation medical device to maintain muscle in the critically ill.
long-arrow-right
